Increased insurance coverage should boost demand for medical services which would highlight concerns about access to medical care, particularly outside of Boston.
Increased insurance coverage should boost demand for medical services which would highlight concerns about access to medical care, particularly outside of Boston.
"Rural areas tend to have a higher percentage of poor and uninsured and fewer doctors. Insurance alone may not assure access," according to B. Dale Magee, MD, MS, president of the Massachusetts Medical Society.
A shortage of primary care physicians in Massachusetts has led many doctors to stop accepting new patients, according to a recent report by the Massachusetts Medical Society. "Primary care physicians should be central to the delivery of healthcare," Dr. Magee says. "Absent a primary care physician, patients tend to distribute their care among specialists, which can lead to more testing and less continuity and drive up expenses. Distribution of physicians-both within the state and the country-is part of the issue and we need to be cognizant of the fact that physicians have choices in where they can live. Incentives to practice in underserved areas need to be more effective. Some specialties, such as primary care, should be compensated in a manner that recognizes their importance. In that end, the financial consequences of a primary care shortage may cost more than appropriate compensation."
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More